Agile Therapeutics, Inc. (NASDAQ:AGRX) Upgraded to Sell at ValuEngine
Agile Therapeutics, Inc. (NASDAQ:AGRX) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Saturday.
AGRX has been the subject of a number of other research reports. FBR & Co set a $10.00 price objective on Agile Therapeutics and gave the company a “buy” rating in a research report on Saturday, March 11th. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Monday, March 13th. Cantor Fitzgerald upped their price objective on Agile Therapeutics from $7.00 to $8.00 and gave the company an “overweight” rating in a research report on Tuesday, April 4th. Finally, Zacks Investment Research cut Agile Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, March 13th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $9.92.
Shares of Agile Therapeutics (NASDAQ:AGRX) traded up 0.27% during midday trading on Friday, reaching $3.73. The company had a trading volume of 40,578 shares. Agile Therapeutics has a 1-year low of $1.82 and a 1-year high of $8.15. The stock’s market capitalization is $107.45 million. The company’s 50-day moving average is $3.65 and its 200-day moving average is $3.34.
In related news, insider Renee Selman purchased 53,333 shares of Agile Therapeutics stock in a transaction on Thursday, May 11th. The stock was acquired at an average price of $3.68 per share, for a total transaction of $196,265.44. Following the completion of the transaction, the insider now directly owns 53,333 shares in the company, valued at approximately $196,265.44. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Alfred Altomari purchased 10,000 shares of Agile Therapeutics stock in a transaction on Thursday, May 11th. The stock was bought at an average price of $3.51 per share, with a total value of $35,100.00. Following the transaction, the chairman now owns 151,587 shares of the company’s stock, valued at $532,070.37. The disclosure for this purchase can be found here. Corporate insiders own 3.50% of the company’s stock.
An institutional investor recently raised its position in Agile Therapeutics stock. Renaissance Technologies LLC increased its position in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 209.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 64,000 shares of the specialty pharmaceutical company’s stock after buying an additional 43,300 shares during the period. Renaissance Technologies LLC owned approximately 0.22% of Agile Therapeutics worth $365,000 at the end of the most recent reporting period. 79.78% of the stock is currently owned by hedge funds and other institutional investors.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.